SILVERARC CAPITAL MANAGEMENT, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001816307

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q1 2025 · 68 positions · Total reported value $477.10M · Top-10 concentration 50.6% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 64.6% · 15 new · 20 cut · 18 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -8.8% · vs SPY -10.9% · Prev Value $855.33M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -4.7% · vs SPY -6.9% · Latest Value $784.53M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q1 2025 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC disclosed 68 equity positions with a combined reported value of $477.10M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 50.6% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2025 were VRNA ($34.66M), MRUS ($34.14M), NUVL ($31.14M). By sector, the heaviest allocations are Health Care 59.5%, Other 40.5%. Versus the prior quarter, allocation shifted toward Other (+2.6pp) and away from Health Care (-2.4pp).

Versus the prior quarter, SILVERARC CAPITAL MANAGEMENT, LLC opened 15 new positions, trimmed 20 and fully exited 18, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 54% of names.

The largest new positions opened in Q1 2025 were NBIX ($8.03M), MLYS ($5.37M), ALKS ($4.12M).

Of the 18 positions fully exited versus the prior quarter, the largest were PLRX ($17.33M), ITCI ($14.96M), PSTX ($9.72M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2025)

  • NBIX NEUROCRINE BIOSCIENCES INC · $8.03M
  • MLYS MINERALYS THERAPEUTICS INC · $5.37M
  • ALKS ALKERMES PLC · $4.12M
  • OCUL OCULAR THERAPEUTIX INC · $4.04M
  • BBIO BRIDGEBIO PHARMA INC · $3.84M
  • KURA KURA ONCOLOGY INC · $3.84M
  • DNTH DIANTHUS THERAPEUTICS INC · $3.45M
  • MDGL MADRIGAL PHARMACEUTICALS INC · $3.43M

Fully Exited (vs previous quarter)

  • PLRX PLIANT THERAPEUTICS INC · prev qtr: $17.33M
  • ITCI INTRA CELLULAR THERAPIES INC · prev qtr: $14.96M
  • PSTX POSEIDA THERAPEUTICS INC · prev qtr: $9.72M
  • SRRK SCHOLAR ROCK HLDG CORP · prev qtr: $7.92M
  • COGT COGENT BIOSCIENCES INC · prev qtr: $7.18M · history
  • RARE ULTRAGENYX PHARMACEUTICAL IN · prev qtr: $5.23M
  • INCY INCYTE CORP · prev qtr: $3.38M
  • PCVX VAXCYTE INC · prev qtr: $3.34M · history

Insider Transactions (Form 4)

Latest SILVERARC CAPITAL MANAGEMENT, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Silverarc Capital Management is an SEC-registered 13F filer based in Boston, MA, United States. As of Q2 2026 it reported 67 US equity positions with a combined value of $855.33M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-116845 (status: Approved), registered 2019-06-21
  • Regulatory AUM (Form ADV): $1.61B as of 2026-03-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 2 hedge funds
  • Website: silverarccapital.com

Portfolio Structure

  • 67 positions · $855.33M reported value (Q2 2026)
  • Top 10 holdings = 47.1% of reported value
  • Largest position: ASND (ASCENDIS PHARMA A/S) at 6.4%
  • Average position size: $12.77M

Sector Tilt

  • Health Care 98.1%
  • Financials 1.9%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 19 new, 16 added, 28 reduced, 20 exited
  • 4 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 59.5%
Other 40.5%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 545.87K $34.66M 7.26%
7.26%
Add
2 811.02K $34.14M 7.16%
7.16%
Add
3 439.02K $31.14M 6.53%
6.53%
Add
4 719.99K $29.15M 6.11%
6.11%
Reduce
5 321.37K $24.52M 5.14%
5.14%
Reduce
6 1.70M $19.61M 4.11%
4.11%
Add
7 633.83K $18.79M 3.94%
3.94%
Add
8 337.61K $17.88M 3.75%
3.75%
Add
9 1.31M $16.08M 3.37%
3.37%
Add
10 1.38M $15.28M 3.20%
3.20%
Add
11 411.31K $12.14M 2.54%
2.54%
Reduce
12 75.75K $11.81M 2.48%
2.48%
Add
13 236.47K $11.74M 2.46%
2.46%
Add
14 2.06M $11.50M 2.41%
2.41%
Add
15 1.51M $10.98M 2.30%
2.30%
Add
16 7.37M $10.09M 2.12%
2.12%
Reduce
17 1.05M $8.49M 1.78%
1.78%
Add
18 72.58K $8.03M 1.68%
1.68%
New
19 408.85K $7.33M 1.54%
1.54%
Add
20 180.60K $7.31M 1.53%
1.53%
Reduce
21 6.32M $6.95M 1.46%
1.46%
Add
22 62.03K $6.95M 1.46%
1.46%
Add
23 613.39K $6.93M 1.45%
1.45%
Add
24 2.67M $6.76M 1.42%
1.42%
Add
25 166.07K $6.29M 1.32%
1.32%
Add
26 338.35K $5.37M 1.13%
1.13%
New
27 2.90M $4.23M 0.89%
0.89%
Add
28 81.33K $4.18M 0.88%
0.88%
Add
29 124.87K $4.12M 0.86%
0.86%
New
30 551.57K $4.04M 0.85%
0.85%
New
31 111.00K $3.84M 0.80%
0.80%
New
32 581.37K $3.84M 0.80%
0.80%
New
33 205.96K $3.74M 0.78%
0.78%
Reduce
34 190.33K $3.45M 0.72%
0.72%
New
35 10.34K $3.43M 0.72%
0.72%
New
36 2.46M $3.41M 0.72%
0.72%
Add
37 2.77M $3.38M 0.71%
0.71%
Reduce
38 232.76K $3.35M 0.70%
0.70%
Reduce
39 530.00K $3.33M 0.70%
0.70%
Reduce
40 37.34K $3.31M 0.69%
0.69%
New
41 188.07K $3.26M 0.68%
0.68%
Add
42 250.00K $3.25M 0.68%
0.68%
New
43 214.06K $3.16M 0.66%
0.66%
New
44 60.39K $3.08M 0.65%
0.65%
New
45 112.76K $3.07M 0.64%
0.64%
New
46 42.50K $3.04M 0.64%
0.64%
New
47 4.10M $2.56M 0.54%
0.54%
Reduce
48 191.47K $2.44M 0.51%
0.51%
Add
49 203.40K $2.16M 0.45%
0.45%
Add
50 88.22K $1.96M 0.41%
0.41%
New

FAQ

What did SILVERARC CAPITAL MANAGEMENT, LLC buy in 2025-Q1?

In its 2025-Q1 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC reported 68 equity positions worth $477.10M in aggregate; its largest disclosed positions were VRNA ($34.66M), MRUS ($34.14M), NUVL ($31.14M).

How large is SILVERARC CAPITAL MANAGEMENT, LLC's portfolio?

SILVERARC CAPITAL MANAGEMENT, LLC reported $477.10M of long equity holdings across 68 positions as of 2025-Q1. Top-10 holdings account for 50.6% of reported value.

What is SILVERARC CAPITAL MANAGEMENT, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/silverarc-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →